Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies

BACKGROUND: The risk for major adverse cardiovascular events (MACE) with targeted therapies for patients with advanced renal cell carcinoma (RCC) in real-world practice remains unclear. OBJECTIVES: The aim of this study was to compare the risk for MACE associated with targeted cancer therapies with...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Dong-Yi, Liu, Jia-Rou, Tseng, Chi-Nan, Hsieh, Ming-Jer, Chuang, Cheng-Keng, Pang, See-Tong, Chen, Shao-Wei, Hsieh, I-Chang, Chu, Pao-Hsien, Chen, Jen-Shi, Wen-Cheng Chang, John, Huang, Wen-Kuan, See, Lai-Chu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270629/
https://www.ncbi.nlm.nih.gov/pubmed/35818552
http://dx.doi.org/10.1016/j.jaccao.2022.05.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270629/
https://www.ncbi.nlm.nih.gov/pubmed/35818552
http://dx.doi.org/10.1016/j.jaccao.2022.05.002

Ejemplares similares